No Data
No Data
William Blair Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Market Expansion and Growth Prospects
Lacklustre Performance Is Driving Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) 26% Price Drop
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
RBC Capital Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $21
RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating